On Friday, Piper Sandler exhibited confidence in argenx SE (NASDAQ: ARGX) shares by increasing the price target on the company's shares to $620 from the previous $553. This adjustment comes in light of argenx's recent financial performance, particularly the strong sales figures for Vyvgart in the third quarter of 2024.
Vyvgart, a treatment for myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), generated $573 million in worldwide revenue during the quarter, surpassing the consensus estimate by approximately $53 million.
The robust sales were attributed to the drug's increased adoption in earlier treatment lines for gMG and a significant number of CIDP patients switching from other treatments, such as intravenous immunoglobulin (IVIG) and steroids.
The analyst maintained an Overweight rating on argenx shares, reflecting a positive outlook on the stock's performance. According to the firm's analysis, the greater-than-expected revenue was a result of insights gathered from neurologist surveys and key opinion leader (KOL) work. These findings highlighted a trend of CIDP patients—85%-90% of whom were previously on IVIG or steroids—switching to Vyvgart.
The management of argenx has indicated that they are not experiencing a sudden influx of CIDP patients, leading to an update in Piper Sandler's financial model. The firm now projects a steady increase in patient numbers, revising its fiscal year 2024 CIDP revenue estimate from $42 million to $78 million.
The analyst emphasized the importance of not overlooking the successful launch of Vyvgart in the gMG market. With this latest financial update, argenx is poised to cement its growing dominance in the neuromuscular disease treatment space, a trend that Piper Sandler anticipates will continue. Encouraging investors to buy, the firm stands by its decision to raise the price target and maintain a bullish stance on argenx shares.
In other recent news, argenx SE has seen a wave of analyst upgrades and downgrades following strong sales and revenue results. Leerink Partners raised their target for argenx to $635, citing robust sales of Vyvgart and Vyvgart Hytrulo. H.C. Wainwright also increased their price target to $617, recognizing the company's impressive quarterly earnings.
However, Baird downgraded argenx from Outperform to Neutral, suggesting limited short-term upside, while William Blair upgraded the stock from Market Perform to Outperform, acknowledging the success of the Vyvgart franchise.
Argenx reported a significant year-over-year increase in global net product revenues, primarily driven by Vyvgart sales, which led to an operating income of $589 million. Despite this, the company recorded a year-to-date operating loss.
Furthermore, argenx recently launched Vyvgart for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), with regulatory reviews ongoing in China, Japan, and Europe, and approvals anticipated in 2025.
These recent developments come as argenx continues to focus on high-impact programs and robust sales growth. However, the company discontinued the development of efgartigimod in MN due to insufficient efficacy. Despite this setback, argenx's strong financial position, backed by a cash balance of $3.4 billion, positions it well for further advancements in its clinical pipeline.
InvestingPro Insights
Building on Piper Sandler's optimistic outlook for argenx SE (NASDAQ: ARGX), recent data from InvestingPro provides additional context to the company's financial position and market performance. The company's market capitalization stands at an impressive $35.48 billion, reflecting investor confidence in its growth potential.
InvestingPro Tips highlight that argenx holds more cash than debt on its balance sheet, indicating a strong financial position that could support ongoing research and development efforts for treatments like Vyvgart. This aligns with the company's ability to capitalize on its recent sales success and potentially fund future innovations in the neuromuscular disease treatment space.
Furthermore, the stock has seen a significant price uptick over the last six months, with a total return of 52.95%. This performance corroborates Piper Sandler's bullish stance and increased price target. The stock is currently trading near its 52-week high, with a price that is 99.44% of its peak, suggesting sustained investor enthusiasm.
It's worth noting that while argenx's revenue growth is robust at 98.69% over the last twelve months, the company is not yet profitable. This is typical for biotechnology companies in growth phases, especially those with recently launched products like Vyvgart.
For investors seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for ARGX, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.